ArticleNeuro-oncology2020
Optimizing eligibility criteria and clinical trial conduct to enhance clinical trial participation for primary brain tumor patients.
Article in Neuro-oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 39 citations in OpenAlex.
- Evaluating a Physician Audit and Feedback Intervention to Increase Clinical Trial Enrollment in Radiation Oncology in a Multisite Tertiary Cancer Center: A Randomized Study.International journal of radiation oncology, biology, physics · 2024Trial
- Precision Immunotherapeutics for Glioblastoma: Current Approaches and Emerging Strategies in 2026.Cells · 2026Review
- Clinical trial design for primary brain tumors: a problem-based framework for neuro-oncology practice.Frontiers in oncology · 2026Review
- Response Assessment in Neuro-Oncology (RANO) 2009-2025: Broad scope and implementation-A progress report.Neuro-oncology · 2025Review
- Identifying appropriate external control datasets in support of future glioblastoma clinical trials leveraging external data.Neuro-oncology · 2025Article
- Design and conduct of theranostic trials in neuro-oncology: Challenges and opportunities.Neuro-oncology · 2024Review
- Glioblastoma Vaccines as Promising Immune-Therapeutics: Challenges and Current Status.Vaccines · 2024Review
- Defining interventions and metrics to improve diversity in CNS clinical trial participation: A SNO and RANO effort.Neuro-oncology · 2024Article
- The Effect of Therapy Regimen on Antitumor Efficacy of the Nanosomal Doxorubicin against Rat Glioblastoma 101.8.Bulletin of experimental biology and medicine · 2024Article
- A critical analysis of neuro-oncology clinical trials.Neuro-oncology · 2023Article
- Recurrent Glioblastoma: Ongoing Clinical Challenges and Future Prospects.OncoTargets and therapy · 2023Review
- The trial effect in patients with glioblastoma: effect of clinical trial enrollment on overall survival.Journal of neuro-oncology · 2022Article
- Analysis of factors leading to early termination in glioblastoma-related clinical trials.Journal of neuro-oncology · 2022Review
- Association between Prior Malignancy Exclusion Criteria and Age Disparities in Cancer Clinical Trials.Cancers · 2022Article
- Glioblastoma Clinical Trials: Current Landscape and Opportunities for Improvement.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022Review
- Review
- Report of National Brain Tumor Society roundtable workshop on innovating brain tumor clinical trials: building on lessons learned from COVID-19 experience.Neuro-oncology · 2021Article
- Primary central nervous system lymphoma: a narrative review of ongoing clinical trials and goals for future studies.Annals of lymphoma · 2021Article
- The effects of releasing early results from ongoing clinical trials.Nature communications · 2021Article
- World Cancer Day 2021 - Perspectives in Pediatric and Adult Neuro-Oncology.Frontiers in oncology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors at 17 institutions in 3 countries.
Funding
Abstract
Building on an initiative to enhance clinical trial participation involving the Society for Neuro-Oncology, the Response Assessment in Neuro-Oncology Working Group, patient advocacy groups, clinical trial cooperative groups, and other partners, we evaluate the impact of eligibility criteria and trial conduct on neuro-oncology clinical trial participation. Clinical trials often carry forward eligibility criteria from prior studies that may be overly restrictive and unnecessary and needlessly limit patient accrual. Inclusion and exclusion criteria should be evaluated based on the goals and design of the study and whether they impact patient safety and/or treatment efficacy. In addition, we evaluate clinical trial conduct as a barrier to accrual and discuss strategies to minimize such barriers for neuro-oncology trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.